PMID- 36286821
OWN - NLM
STAT- MEDLINE
DCOM- 20221028
LR  - 20221207
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 93
IP  - 10
DP  - 2021 Oct 15
TI  - [Retrospective analysis of clinical outcomes of patients with COVID-19 depending 
      on receiving antihypertensive, lipid-lowering and antihypertensive therapy].
PG  - 1193-1202
LID - 10.26442/00403660.2021.10.201072 [doi]
AB  - BACKGROUND: The main factors that increase the risk of cardiovascular accidents 
      and mortality among patients with COVID-19 include hyperglycemia, arterial 
      hypertension and dyslipidemia. Therefore, all patients with COVID-19 and 
      metabolic syndrome should receive antihypertensive (AHT), hypolipidemic (GLT) and 
      hypoglycemic therapy (GGT). Currently, there is a limited number of studies 
      regarding the effectiveness and safety of this therapy in patients with COVID-19. 
      AIM: Evaluate the clinical outcomes of patients with COVID-19, depending on the 
      recipient of AHT, GLT and GGT. MATERIALS AND METHODS: A retrospective analysis of 
      the clinical outcomes "discharged/died" of 1753 patients with COVID-19 was 
      carried out depending on the received AHT, GLT and GGT. RESULTS: A significant 
      reduction in the risk of mortality among patients with COVID-19 was observed 
      during therapy with angiotensin-converting enzyme inhibitors/angiotensin II 
      receptor blockers ACE inhibitors/ARBs (OR 0.39, 95% CI 0.210.72; p0.05) and 
      b-adrenergic blockers b-AB (OR 0.53, 95% CI 0.281; p0.05). At the same time, 
      against the background of therapy with ACE inhibitors/ARBs and b-ABs, the chance 
      of mortality decreased more significantly among patients with type 2 diabetes 
      mellitus (T2DM) compared with patients without T2DM. Diuretic therapy was 
      associated with a 3-fold increase in the chances of death: OR 3.33, 95% CI 
      1.884.79; p0.05. Statin therapy did not affect clinical outcomes in COVID-19 
      patients. On the background of therapy with oral hypoglycemic drugs, the risk of 
      mortality decreased 5-fold (OR 0.19, 95% CI 0.070.54; p0.05). Against the 
      background of insulin therapy, there was an increase in mortality risk by 2.8 
      times (OR 2.81, 95% CI 1.55.29; p0.05). CONCLUSION: A significant reduction in 
      mortality among patients with COVID-19 was observed during therapy with ACEI/ARB, 
      b-AB, and oral hypoglycemic therapy. Increased risk of death was associated with 
      insulin therapy and diuretic therapy.
FAU - Demidova, T Y
AU  - Demidova TY
AUID- ORCID: 0000-0001-6385-540X
AD  - Pirogov Russian National Research Medical University.
FAU - Lobanova, K G
AU  - Lobanova KG
AUID- ORCID: 0000-0002-3656-0312
AD  - Pirogov Russian National Research Medical University.
FAU - Perekhodov, S N
AU  - Perekhodov SN
AUID- ORCID: 0000-0002-6276-2305
AD  - Demikhov Clinical City Hospital.
FAU - Antsiferov, M B
AU  - Antsiferov MB
AUID- ORCID: 0000-0002-9944-2997
AD  - Endocrinological Dispensary.
FAU - Oynotkinova, O S
AU  - Oynotkinova OS
AUID- ORCID: 0000-0002-9856-8643
AD  - Pirogov Russian National Research Medical University.
LA  - rus
PT  - English Abstract
PT  - Journal Article
DEP - 20211015
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Adrenergic Antagonists)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Diuretics)
RN  - 0 (Insulins)
RN  - 0 (Lipids)
SB  - IM
MH  - Humans
MH  - Antihypertensive Agents/adverse effects
MH  - Angiotensin Receptor Antagonists/adverse effects
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - *Hypertension/drug therapy/complications
MH  - Adrenergic Antagonists/therapeutic use
MH  - Hypoglycemic Agents/adverse effects
MH  - Diuretics
MH  - *Insulins/therapeutic use
MH  - Lipids
MH  - *COVID-19 Drug Treatment
OTO - NOTNLM
OT  - COVID-19
OT  - antihypertensive drugs
OT  - favipiravirum
OT  - hypertension
OT  - hypoglycemic drugs
OT  - type 2 diabetes mellitus
EDAT- 2022/10/27 06:00
MHDA- 2022/10/29 06:00
CRDT- 2022/10/26 09:54
PHST- 2021/11/04 00:00 [received]
PHST- 2021/11/04 00:00 [accepted]
PHST- 2022/10/26 09:54 [entrez]
PHST- 2022/10/27 06:00 [pubmed]
PHST- 2022/10/29 06:00 [medline]
AID - 10.26442/00403660.2021.10.201072 [doi]
PST - epublish
SO  - Ter Arkh. 2021 Oct 15;93(10):1193-1202. doi: 10.26442/00403660.2021.10.201072.